Offered by: Nemours Children's
Location: Delaware Valley
Experiences and Decision-Making for CFTR Modulators: A Qualitative Analysis
To explore the experience of patients and families in the CF Community related to highly effective CFTR modulator therapy (HEMT). These medications include: Ivacaftor (Kalydeco®), Tezacaftor/Ivacaftor (Symdeko®), and Elexacaftor/Tezacaftor/Ivacaftor (Trikafta®).
Children/adolescents with CF (ages 12-17); Adults with CF (18 and older); and Caregivers (e.g., parents or guardians) of individuals with CF.
If you provide consent for your participation, we will ask you to participate in a 30-60 minute phone or telehealth interview about your feelings and experiences around highly effective CFTR modulator therapy (HEMT). HEMT therapy includes the medications: Ivacaftor (Kalydeco®), Tezacaftor/ivacaftor (Symdeko®), and Elexacaftor/Tezacaftor/Ivacaftor (Trikafta®). We are interested in hearing about your experience and perspective whether or not you take these medications.
We will also ask you to complete a background questionnaire, which includes personal questions related to you and your family.
Trial Name: Experiences and Decision-Making for CFTR Modulators: A Qualitative Analysis
IRB# 1763755
(800) 354-5690 Email UsLearn more about clinical trials and get answers to questions you might have.
Go to FAQs View All Clinical TrialsNemours has a number of service regions. Selecting your region will help us show you the right contact information and the most relevant content for you.